Bristol Offloads HIV Pipeline To ViiV As It Tightens Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal brings GSK/Pfizer HIV-focused affiliate two novel mechanisms, one of which could be used in combination with Tivicay and another that addresses a different stage of the virus' lifecycle than any HIV drug now approved.
You may also be interested in...
ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value
The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.
Bristol Advancing Two New Mechanisms In HIV, With Focus On Treatment-Experienced Patients
An attachment inhibitor entering Phase III may offer a new option for patients who have outlived the utility of other antiretrovirals. Bristol also is advancing a second-generation maturation inhibitor of HIV into Phase IIb studies, hoping to succeed where other candidates failed to address viral mutation.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.